In contrast to these studies, which consider CLL patients independent of IGHV gene SHM status, we recently provided preliminary evidence that different markers were relevant in U-CLL versus M-CLL; i.e., TP53 abnormalities, del(11q) and/or SF3B1 mutations in U-CLL and TP53 abnormalities, trisomy 12 and stereotyped subset #2 membership in M-CLL [31]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.